Relmada Therapeutics, Inc.
NASDAQ: RLMD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sergio Traversa
- Employees
- 17
- Headquarters
- Coral Gables, United States
- IPO year
- 2014
- Market cap
- $477.4M
- Website
- https://www.relmada.com
Loading RLMD…
Loading profile data…Frequently asked questions about RLMD
What does Relmada Therapeutics, Inc. (RLMD) do?
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranol...
Where does RLMD trade?
Relmada Therapeutics, Inc. (RLMD) trades on the NASDAQ.
What sector is RLMD in?
Relmada Therapeutics, Inc. (RLMD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Relmada Therapeutics, Inc.?
Sergio Traversa is the chief executive officer of Relmada Therapeutics, Inc. (RLMD).
Where is Relmada Therapeutics, Inc. headquartered?
Relmada Therapeutics, Inc. is headquartered in United States.
Does RLMD pay a dividend?
Relmada Therapeutics, Inc. (RLMD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RLMD go public?
Relmada Therapeutics, Inc. (RLMD) completed its initial public offering in 2014.